niacinamide has been researched along with pyrazines in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (13.33) | 29.6817 |
| 2010's | 22 (73.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Neurath, G | 1 |
| Dulin, WE; Wyse, BM | 1 |
| Cuthbert, AW; Edwardson, JM | 1 |
| Adjei, AA; Carter, CA; Friday, BB; Kaufmann, SH; Kay, NE; Lai, JP; Roberts, LR; Sarkaria, J; Yang, L; Yu, C | 1 |
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 1 |
| Bauer, S; Bode, B; Knuth, A; Liewen, H; Renner, C; Samaras, P; Stenner, F; Tchinda, J; Weber, A; Zweifel, M | 1 |
| Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC | 1 |
| Davies, L; Hedley, D; Kirk, R; Lopes, F; Manne, HA; Marais, R; Ménard, D; Niculescu-Duvaz, D; Niculescu-Duvaz, I; Nourry, A; Ogilvie, LM; Preece, N; Springer, CJ; Suijkerbuijk, BM; Whittaker, S; Zambon, A | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE | 1 |
| Buettner, R; Chang, S; Hedvat, M; Jove, R; Jove, V; Liu, L; Scuto, A; Tian, Y; Van Meter, T; Wen, W; Yang, F; Yen, Y; Yip, ML | 1 |
| Gupta, S | 1 |
| Bornfeld, N; Freistuehler, M; Hilger, RA; Scheulen, M; Steuhl, KP; Westekemper, H | 1 |
| Badole, SL; Bagul, PP; Bodhankar, SL; Coutinho, EC; Ghule, AE; Joshi, AC; Khedkar, VM; Khose, RD; Mahamuni, SP; Raut, CG; Wagh, NK | 1 |
| Catusse, J; Engelhardt, M; Follo, M; Ihorst, G; Schnerch, D; Schüler, J; Udi, J; Waldschmidt, J; Wäsch, R; Wider, D | 1 |
| Badole, SL; Bagul, PP; Coutinho, EC; Ghule, AE; Jangam, GB; Joshi, AC; Khedkar, VM; Khose, RD; Mahamuni, SP; Raut, CG | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R | 1 |
| Adjei, AA; Bible, KC; Croghan, G; Erlichman, C; Jett, J; Kaufmann, SH; Kumar, SK; Markovic, SN; Marks, R; Molina, J; Moynihan, T; Qin, R; Quevedo, F; Richardson, R; Tan, A | 1 |
| Badole, SL; Bagul, PP; Chaudhari, SM; Joshi, AC; Khose, RD; Mahamuni, SP; Raut, CG; Zanwar, AA | 1 |
| Aplenc, R; Caparas, M; Cullen, P; Johnston, DL; Nagarajan, R; Schulte, F; Sung, L | 1 |
| Choi, Y; Hur, DY; Kim, D; Kim, YS; Lee, HK; Park, GB | 1 |
| Biggers, WJ; Burns, RT; Lehman, C; Pechenik, JA; Scavo, G | 1 |
| Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
| Baillie, TA; Cyrus Khojasteh, S; Dalvie, D; Rietjens, IM | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Achanta, PS; Chen, SN; Pauli, GF | 1 |
4 review(s) available for niacinamide and pyrazines
| Article | Year |
|---|---|
[Nitrogen compounds of tobacco smoke].
Topics: Acridines; Alkaloids; Alkanes; Amines; Amino Acids; Aniline Compounds; Carbazoles; Cyanates; Indoles; Isoquinolines; Ketones; Niacinamide; Nicotiana; Nicotine; Nicotinic Acids; Nitriles; Nitrites; Nitrosamines; Piperidines; Plants, Toxic; Pyrazines; Pyridines; Pyrroles; Pyrrolidines; Quinolines; Quinoxalines; Smoking | 1969 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Immunotherapies in diabetes mellitus type 1.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Azathioprine; Basiliximab; Chaperonin 60; Cyclosporine; Daclizumab; Diabetes Mellitus, Type 1; Diet; Etanercept; Exenatide; Fatty Acids, Unsaturated; Glutamate Decarboxylase; Humans; Hypoglycemic Agents; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Insulin; Interferon-alpha; Interleukin 1 Receptor Antagonist Protein; Islets of Langerhans Transplantation; Niacinamide; Peptide Fragments; Peptides; Primary Prevention; Pyrazines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Rituximab; Secondary Prevention; Sitagliptin Phosphate; Tertiary Prevention; Triazoles; Venoms; Vitamin D; Vitamins | 2012 |
Biotransformation and bioactivation reactions - 2015 literature highlights.
Topics: Acetaminophen; Allylbenzene Derivatives; Aniline Compounds; Animals; Anisoles; Benzbromarone; Biotransformation; Humans; Imidazoles; Niacinamide; Nitroimidazoles; Nitrosamines; Oxazoles; Oxazolidinones; Peroxides; Pyrazines; Pyrazoles; Pyridazines; Pyridines; Pyridones; Pyrimidinones; Thiophenes; Triazoles | 2016 |
5 trial(s) available for niacinamide and pyrazines
| Article | Year |
|---|---|
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate | 2012 |
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Group Processes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Parents; Phenylurea Compounds; Pyrazines; Quality of Life; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Young Adult | 2013 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
21 other study(ies) available for niacinamide and pyrazines
| Article | Year |
|---|---|
Studies on the ability of compounds to block the diabetogenic activity of streptozotocin.
Topics: Amino Acids; Animals; Diabetes Mellitus; Diaphragm; Diazoxide; Epinephrine; Ethanol; Glucosamine; Glucose; Hyperglycemia; Hypoglycemic Agents; Male; NAD; Niacinamide; Nitroso Compounds; Pyrazinamide; Pyrazines; Pyrazoles; Rats; Tolbutamide | 1969 |
Benzamil binding to kidney cell membranes.
Topics: Amiloride; Animals; Binding Sites; Cell Membrane; Chickens; Fishes; Guinea Pigs; In Vitro Techniques; Kidney; Microvilli; Niacinamide; Pyrazines; Rabbits; Ranidae; Rats; Species Specificity | 1981 |
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; K562 Cells; MAP Kinase Signaling System; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2006 |
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; L-Lactate Dehydrogenase; Niacinamide; Phenylurea Compounds; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyridines; Sorafenib | 2007 |
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2009 |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Okadaic Acid; Phenylurea Compounds; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Biological Availability; Crystallography, X-Ray; Female; Humans; Hydrogen Bonding; Imidazoles; Mice; Mice, Inbred BALB C; Models, Molecular; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Binding; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Structure-Activity Relationship; Transplantation, Heterologous | 2010 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cerebellar Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytochromes c; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Medulloblastoma; NF-kappa B; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Sorafenib; Tumor Cells, Cultured | 2012 |
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.
Topics: Antineoplastic Agents; Benzophenones; Boronic Acids; Bortezomib; Cell Proliferation; Conjunctival Neoplasms; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazines; Ribonucleases; Sorafenib; Tumor Cells, Cultured | 2013 |
Cycloart-23-ene-3β, 25-diol stimulates GLP-1 (7-36) amide secretion in streptozotocin-nicotinamide induced diabetic Sprague Dawley rats: a mechanistic approach.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drinking; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucose Tolerance Test; Insulin; Male; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Pancreas; Peptide Fragments; Protein Conformation; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Time Factors; Triazoles; Triterpenes | 2013 |
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
Topics: Actins; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemokine CXCL12; Chemotaxis; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Polymerization; Pyrazines; Sorafenib; Syndecan-1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Colon; Diabetes Mellitus, Experimental; Drinking; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Glutamine; Glycated Hemoglobin; Insulin; Lipid Metabolism; Male; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Pancreas; Peptide Fragments; Protein Conformation; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Colon; Diabetes Mellitus, Experimental; Drinking Behavior; Feeding Behavior; Glucagon-Like Peptide 1; Glutamine; Glycated Hemoglobin; Insulin; Lipid Metabolism; Male; Niacinamide; Oxidative Stress; Pancreas; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Staining and Labeling; Streptozocin; Triazoles; Triterpenes | 2013 |
Silencing of PKCη induces cycle arrest of EBV(+) B lymphoma cells by upregulating expression of p38-MAPK/TAp73/GADD45α and increases susceptibility to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drug Resistance, Neoplasm; Herpesvirus 4, Human; Humans; Membrane Potential, Mitochondrial; NF-kappa B; Niacinamide; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase C; Pyrazines; RNA Interference; RNA, Small Interfering; Sorafenib; Tumor Protein p73; Tumor Suppressor Proteins; Up-Regulation | 2014 |
The B vitamins nicotinamide (B3) and riboflavin (B2) stimulate metamorphosis in larvae of the deposit-feeding polychaete Capitella teleta: implications for a sensory ligand-gated ion channel.
Topics: Animals; Biological Assay; Calcium; Imidazoles; Ketanserin; Larva; Ligand-Gated Ion Channels; Metamorphosis, Biological; Niacinamide; Polychaeta; Pyrazines; Pyridines; Riboflavin; Seawater | 2014 |
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1 | 2018 |
Plain
Topics: Amides; Antiviral Agents; Drug Contamination; Niacinamide; Proton Magnetic Resonance Spectroscopy; Pyrazinamide; Pyrazines; Quality Control; World Health Organization | 2021 |